Combination targeted adjuvant therapy doubles relapse-free survival in…
LUGANO-MADRID, 11 September, 2017 – Combination targeted adjuvant therapy with dabrafenib and trametinib doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to...















